References
- Kanavos P, Ferrario A, Vandoros S, Anderson GF. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff (Millwood). 2013; 32(4): 753–61.
- Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law. 2011; 6(3): 337–67.
- Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: Evidence from nine countries. Health Aff (Millwood). 2003 Suppl Web Exclusives W3-521-36.
- Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: How large, and why?. J Health Econ. 2000; 19(2): 159–95.
- Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health Aff (Millwood). 2008; 27(1): 221–33.
- Department of Health. Pharmaceutical Price Regulation Scheme: 11th Report to Parliament. 2012. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215156/dh_132793.pdf [cited 22 June 2016].
- Johnson G. Mark-up vs. Margin and its impact on international pharma pricing dynamics. Available from: http://www.celforpharma.com/insight/mark-vs-margin-and-its-impact-international-pharma-pricing-dynamics [cited 22 June 2016].
- Berndt ER, Joseph P. Newhouse. Pricing and Reimbursement in U.S. Pharmaceutical Markets. National Bureau of Economic Research Working Paper No. 16297; 2010. Available from: http://www.nber.org/papers/w16297 [cited 9 June 2016]..
- Kanavos P, Schurer W, Vogler S. The pharmaceutical distribution chain in the European Union: Structure and impact on pharmaceutical prices. London School of Economics Research Online; 2011. Available from: http://eprints.lse.ac.uk/51051/[cited 9 June 2016]..
- The Association of the British Pharmaceutical Industry (ABPI). The pharmaceutical industry and market in the UK (Figure 3 – International price comparisons). Available from: http://www.abpi.org.uk/industry-info/knowledge-hub/uk-economy/Pages/uk-industry-market.aspx [cited 21 June 2016].
- Jørgensen J, Kefalas P. Reimbursement of licensed cell and gene therapies across the major European healthcare markets. J Mark Access Health Policy. 2015; 3: 29321. doi: http://dx.doi.org/10.3402/jmahp.v3.29321.
- Scottish Medicines Agency (SMC). SMC advice directory; 2016. Available from: https://www.scottishmedicines.org.uk/SMC_Advice/Advice_Directory/SMC_Advice_Directory [cited 22 June 2016].
- Scottish Medicines Agency (SMC). A guide to the Scottish Medicines Consortium. 2016. Available from: https://www.scottishmedicines.org.uk/About_SMC/What_we_do/SMC_Guide__web___final_.pdf [cited 22 June 2016].
- National Institute for Health and Care Excellence (NICE). Guide to the processes of technology appraisal. 2014. Available from: https://www.nice.org.uk/article/pmg19/resources/non-guidance-guide-to-the-processes-of-technology-appraisal-pdf [cited 27 June 2016].
- Medicines Complete Online. Available from: www.medicinescomplete.com/ [cited 2 June 2016].
- British National Formulary. How to use the BNF; 2015. Available from: https://www.bnf.org/wp-content/uploads/2015/08/How-to-use-the-BNF.pdf [cited 23 June 2016].
- GoodRx Online. Available from: www.goodrx.com [cited 22 June 2016].
- The Red Book Online. Available from: https://www.micromedexsolutions.com/home/dispatch [cited 22 June 2016].
- UKForex Foreign Exchange Services. Available from: http://www.ukforex.co.uk/ [cited 22 June 2016].
- NHS England. High cost drugs. Available from: https://www.england.nhs.uk/resources/pay-syst/drugs-and-devices/high-cost-drugs/ [cited 22 June 2016].
- European Parliament and Council. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products; 2000. [English version]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf [cited 22 June 2016].
- The national Institute for Health and Care Excellence (NICE). NICE citizens council report – Ultra orphan drugs; 2004. Available from: https://www.nice.org.uk/Media/Default/Get-involved/Citizens-Council/Reports/CCReport04UltraOrphanDrugs.pdf [cited 22 June 2016].